ATLANTA, GA – – (Globe Newswire – February 12, 2025) – – A shareholder class action lawsuit has been filed against Intellia Therapeutics, Inc. (“Intellia” or the “Company”) (NASDAQ: NTLA). The lawsuit alleges that Defendants made material misrepresentations concerning Intellia’s Phase 1/2 study evaluating NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated lung disease.

If you bought shares of Intellia between July 30, 2024 and January 8, 2025, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com/case/intellia-therapeutics/ to learn more.

The deadline to ask the court to be appointed lead plaintiff in the case is April 14, 2025.